OOPAT as SIDNIB as Monotherapy in SLE

OOPAT as SIDNIB as monotherapy in SLE and just a couple of things. The added molecule, the BTK didn't do anything. There was no added value with the two drugs combo instead of the one drug. And the placebo rate was kind of modest to moderate, which we do expect. No new safety signals, including no MI's or no imbalance of VTE or PEDBT when you look at that. So I think it's kind of interesting, maybe a new potential on another oral treatment and we'll see what both these drugs do in Phase III. Although, nothing has been approved for hematologic reasons this year,. but there are trials underway